Page 5 - Controlled Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article CENTENNIAL, Colo., Feb. 23, 2021 /PRNewswire/ --  AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced the first patients have been enrolled in its clinical study titled, A Randomized, Controlled Study to Evaluate Effectiveness of AlloWrap® Amniotic Membrane for the Reduction of Post-Operative Soft Tissue Inflammation in Two-Level Anterior Cervical Discectomy and Fusion (ACDF) Procedures. There are an estimated 300,000 ACDF procedures performed annually in the United States.  Despite the over...

Servicemembers are particularly at risk for Lyme disease; they live, work, and play on bases where Lyme is rampant. Some 75 percent of all U.S. military installations are located in states where 99 percent of the approximately 500,000 tickborne disease,

There is particular interest in monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of COVID-19.